The role of p53 and its molecular circuitry at the mitochondria has not been carefully ascertained in neuroblastoma cells, but further investigation appears necessary for a better understanding of the effects of MDM2–p53 antagonists in neuroblastoma and might help identifying potential biomarkers (in addition to p53 mutational status) to be used for a MDM2–p53 antagonists tailored therapy. This evidence concerns the gene MDM2 and neuroblastoma.